The Three Latest Developments in in-Vitro Diagnostics
By MedTech Outlook | Wednesday, June 19, 2019
The steady growth of chronic and infectious diseases, combined with the rise in aging population, has fuelled the development of in vitro diagnostics (IVD). The need for seamless bedside testing has led to the integration of molecular diagnostics and personalized medicines with diagnostic testing.
The emergence of microfluidics technology has not only enabled organizations to shorten current assays, but also to form diagnoses with a smaller footprint. A few decades past, the tests were conducted in 96-well microplates. It had not only large footprints but also required extensive processing stations.
The recent developments in the IVD technology have introduced new products and services into the market, augmenting direct-to-consumer tests (DTC), point-of-care (POC) diagnostics, and next-generation sequencing. The adoption of these technologies will aid the organizations in gene sequencing and editing operations.
The aging population has necessitated the shift of focus toward POC, facilitating the integration of various technologies to provide innovative solutions. Several healthcare organizations have taken steps toward personalized medicine. However, its applications are still limited. In the case of cancer diagnostics, even though the genome sequencing of tumors has proved a useful tool, the ability of cancer cells to mutate and transform their genomes often renders the treatment ineffective.
Next-Generation Sequencing (NGS)
The innovations in IVD technology have enabled the migration of assays from microplates to single sample chips. It has allowed organizations to perform multiple tests to extract vast information from a single drop of blood, urine, and so on. Also, the emergence of next-generation sequencing (NGS) and anti-microbial stewardship, combined with the rise of Ebola and plague, has increased the importance of prompt diagnosis.
Owing to the technological evolutions over the last decade, the patients have come to expect beneficial upgrades in the healthcare industry. Hence, it is necessary for organizations to adopt robust technologies capable of handling vast troves of data, while at the same time, ensuring its secure storage and management.
There is a need for the regulatory landscape to accommodate innovators, facilitating a seamless compliance approach to encourage more investors to commit to the projects. The increase in funding will spur smaller organizations to streamline their diagnostics research and assist them in taking their projects to the development stage.